万达轴承(920002) - 2025 Q4 - 年度业绩
2026-02-26 09:15
Financial Performance - The company achieved operating revenue of ¥353,159,911.10, representing a year-on-year increase of 2.16%[5] - Total profit reached ¥71,836,641.62, reflecting a growth of 7.59% compared to the previous year[5] - Net profit attributable to shareholders was ¥62,676,195.15, up by 8.87% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥55,144,055.86, showing a slight increase of 0.70%[5] - Basic earnings per share increased to ¥1.38, a growth of 2.99% from the previous year[5] Assets and Equity - Total assets at the end of the reporting period were ¥818,247,259.99, marking a 10.00% increase year-on-year[5] - Shareholders' equity attributable to the company reached ¥737,543,583.41, up by 8.77%[5] - The total share capital increased by 40.00% to ¥45,502,968.00 due to capital reserve conversion[6] - The net asset per share attributable to shareholders decreased by 22.29% to ¥16.21[5] Cautionary Notes - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[7]
硅烷科技(920402) - 2025 Q4 - 年度业绩
2026-02-26 09:15
2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示:本公告所载 2025 年年度主要财务数据为初步核算数据,未经会 计师事务所审计,具体数据以公司 2025 年年度报告中披露的数据为准,提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 单位:元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 473,960,171.58 | 705,432,483.79 | -32.81% | | 利润总额 | -116,447,482.01 | 84,435,313.75 | - | | 归属于上市公司股 | -110,058,788.08 | 77,673,266.94 | - | | 东的净利润 | | | | | 归属于上市公司股 | -113,751,178.01 | 70,394,790.33 | | | 东的扣除非经常性 | | | - | | 损益的净利润 | | | | ...
森萱医药(920946) - 2025 Q4 - 年度业绩
2026-02-26 09:15
Financial Performance - The company achieved operating revenue of ¥552,577,290.50, representing a year-on-year increase of 2.87%[3] - The total profit amounted to ¥159,045,522.15, reflecting an 8.04% increase compared to the previous year[3] - Net profit attributable to shareholders reached ¥131,575,798.33, up by 6.32% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥127,969,849.80, marking a 9.64% increase[3] - Basic earnings per share were ¥0.3082, which is a 6.32% increase from the previous year[3] Assets and Equity - Total assets at the end of the reporting period were ¥1,443,815,065.38, showing a growth of 6.62%[3] - Shareholders' equity attributable to the company was ¥1,265,354,551.40, an increase of 6.21%[3] Market and Operational Strategy - The company maintained stable revenue and profit growth despite slight price declines in some domestic products due to competition and policy factors[5] - The increase in revenue and profit was significantly supported by the growth in overseas sales of new and existing raw materials[5] - The company focused on optimizing management and reducing costs to enhance product competitiveness, ensuring stable revenue and gross profit growth[5]
热景生物(688068) - 2025 Q4 - 年度业绩
2026-02-26 09:15
Financial Performance - Total revenue for 2025 was CNY 407.69 million, a decrease of 20.20% compared to the previous year[3] - Net profit attributable to shareholders was CNY -210.52 million, down 10.22% year-over-year[3] - The decline in revenue and net profit was primarily due to industry policy impacts, including price reductions and decreased demand, resulting in a revenue drop of CNY 103.21 million[5] - The operating profit and total profit decreased significantly due to asset impairment provisions and increased R&D expenditures[8] Assets and Equity - The company's total assets at the end of the reporting period were CNY 3,081.56 million, a decline of 7.35% from the previous year[4] - Shareholders' equity attributable to the parent company decreased by 19.04% to CNY 2,489.86 million[4] Impairment and Losses - The company recognized impairment losses of CNY 38.01 million on related operating assets during the reporting period[5] - The company reported an investment loss of CNY 13.51 million from joint ventures in the field of biopharmaceutical innovation[7] Research and Development - R&D investment for the newly controlled subsidiary, ShunJing Pharmaceutical, amounted to CNY 78.62 million[6] Financial Reporting - Investors are advised to note that the financial data presented are preliminary and unaudited, with final figures to be disclosed in the annual report[9]
金冠电气(688517) - 2025 Q4 - 年度业绩
2026-02-26 09:15
Financial Performance - In 2025, the company achieved total operating revenue of RMB 730.48 million, an increase of 11.04% compared to the previous year[4] - The net profit attributable to the parent company was RMB 81.22 million, a decrease of 10.87% year-on-year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 72.91 million, down 11.41% from the previous year[4] - The company's total assets at the end of 2025 were RMB 1,352.99 million, reflecting a growth of 5.61% from the beginning of the period[4] - The equity attributable to the parent company was RMB 819.76 million, an increase of 0.60% from the beginning of the period[4] - The basic earnings per share decreased to RMB 0.59, down 11.94% from RMB 0.67 in the previous year[4] - The weighted average return on net assets decreased by 1.42 percentage points to 9.94%[4] Revenue Drivers - Sales orders for surge protectors, resistors, and charging pile products continued to grow, contributing to the overall revenue increase[7] Profitability Challenges - The gross profit margins for distribution network products and charging pile products declined due to market competition and cost factors, impacting overall profitability[7] - There were no financial data or indicators with a change of 30% or more during the reporting period[7]
财富趋势(688318) - 2025 Q4 - 年度业绩
2026-02-26 09:15
Financial Performance - Total revenue for the reporting period was CNY 368,582,241.78, a decrease of 5.25% compared to the same period last year[5] - Net profit attributable to the parent company was CNY 314,947,149.35, an increase of 3.62% year-on-year[5] - Net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 246,534,869.68, a decrease of 9.13% year-on-year[5] - Basic earnings per share were CNY 1.23, an increase of 3.36% compared to the previous year[3] - The weighted average return on net assets decreased by 0.19 percentage points to 8.47%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 4,054,242,734.10, an increase of 6.10% from the beginning of the period[5] - Equity attributable to the parent company was CNY 3,839,264,071.45, an increase of 6.28% from the beginning of the period[5] - The company's share capital increased by 40% due to the capitalization of capital reserves during the reporting period[6] Market and Operational Strategy - The company faced a decline in software and hardware sales revenue due to reduced demand from institutional clients in the securities market[5] - The company plans to increase R&D investment, enhance operational capabilities, and optimize product structure to improve performance in the future[5]
全志科技(300458) - 2025 Q4 - 年度业绩
2026-02-26 09:14
Financial Performance - Total revenue for 2025 reached CNY 283,795.26 million, a year-on-year increase of 24.04%[5] - Net profit attributable to shareholders was CNY 26,207.31 million, reflecting a growth of 57.17% compared to the previous year[5] - Basic earnings per share increased to CNY 0.32, representing a growth of 60.00% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 23,176.74 million, a significant increase of 100.07% year-on-year[5] - The weighted average return on equity rose to 8.65%, an increase of 3.02 percentage points year-on-year[5] Assets and Equity - Total assets at the end of the reporting period were CNY 379,367.81 million, up 7.01% from the beginning of the period[7] - The company's equity attributable to shareholders grew to CNY 311,426.75 million, a 4.05% increase from the beginning of the period[7] Research and Development - The company's R&D expenses increased by 12.08% during the reporting period, indicating a strong commitment to innovation[7] Product Expansion - The company actively expanded its product lines, particularly in the sweeping robot, smart vision, and smart industrial sectors, contributing to revenue growth[7] Performance Forecast - There were no significant discrepancies between the reported performance and the previous earnings forecast issued on January 20, 2026[8]
沪江材料(920204) - 2025 Q4 - 年度业绩
2026-02-26 09:10
南京沪江复合材料股份有限公司 2025 年年度业绩快报公告 证券代码:920204 证券简称:沪江材料 公告编号:2026-005 二、经营业绩和财务状况情况说明 (一)报告期的经营情况、财务状况及影响经营业绩的主要因素 报告期内,公司实现营业总收入预计为 322,052,934.16 元,同比增长 9.57%; 归属于上市公司股东的净利润预计为 20,867,078.73 元,同比下降 16.54%;归属 于上市公司股东的扣除非经常性损益的净利润预计为 20,128,211.22 元,同比下 降 12.99%;基本每股收益预计为 0.2213 元,同比下降 16.55%。 报告期末,公司总资产预计为 634,426,357.69 元,同比增长 3.03%;归属于 上市公司股东的所有者权益预计为 492,205,490.84 元,同比增长 3.19%;归属于 上市公司股东的每股净资产 5.22 元,同比增长 3.16%。 (二)业绩变动的主要原因 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示 ...
亿能电力(920046) - 2025 Q4 - 年度业绩
2026-02-26 09:10
证券代码:920046 证券简称:亿能电力 公告编号:2026-002 无锡亿能电力设备股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示:本公告所载 2025 年 年度主要财务数据为初步核算数据,未经会 计师事务所审计,具体数据以公司 2025 年年度报告中披露的数据为准,提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 单位:元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 210,274,239.63 | 180,417,281.43 | 16.55% | | 利润总额 | 17,570,389.67 | 15,346,630.11 | 14.49% | | 归属于上市公司股 | 15,005,566.18 | 13,958,547.66 | 7.50% | | 东的净利润 | | | | | 归属于上市公司股 东的扣除非经常性 | 13,450,5 ...
华原股份(920837) - 2025 Q4 - 年度业绩
2026-02-26 09:10
证券代码:920837 证券简称:华原股份 公告编号:2026-003 广西华原过滤系统股份有限公司 2025 年年度业绩快报 报告期末,公司预计总资产为 947,405,933.64 元,较期初增长 4.71%;归 属于上市公司股东的所有者权益为 569,702,281.59 元,较期初增长 7.93%;股 本 151,712,787.00 元,较期初持平;归属于上市公司股东的每股净资产为 3.76 元,较期初增长 8.05%。 二、经营业绩和财务状况情况说明 (二)业绩变动的主要原因 (一)报告期的经营情况、财务状况及影响经营业绩的主要因素 公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 报告期内,公司预计实现营业收入 603,630,866.34 元,同比增长 14.58%; 归属于上市公司股东的净利润为 75,086,974.07 元,同比增长 16.02%;归属于 上市公司股东的扣除非经常性损益的净利润为 71,464,099.41 元,同比增长 22.39%;基本每股收益为 0.49 ...